FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W7870110> ?p ?o ?g. }

• W7870110 endingPage "6" @default.
• W7870110 startingPage "61" @default.
• W7870110 abstract "Polio eradication is within our grasp and, unless something terribly wrong and unexpected happens, the three types of wild polioviruses will cease to circulate in human populations within the next few years. This achievement will be a result of the rational use of OPV. A momentous global decision--discontinuation of vaccination--will then have to be taken. The most important uncertainty that will weigh upon that decision is whether wild polioviruses can re-emerge after eradication defined as complete interruption of wild polioviruses transmission, has been obtained. It is important to realise that eradication does not mean extinction in the sense that the dodo is extinct. After eradication, wild polioviruses will still lurk in laboratory specimens and in protected environmental sites (like glaciers) and may even re-emerge by back mutation or recombination of Sabin-derived strains that may continue to circulate even after OPV use is discontinued. Theoretically, the risk of re-emergence of wild polioviruses would be lessened if IPV was used for a number of years to immunise all those born after cessation of OPV usage. But the question is by how much?. Vaccination with IPV will reduce the risk that persistent OPV-derived strains (e.g. in immunodeficient patients) will have the chance to establish permanent transmission after vaccination is totally discontinued. However, the risk of re-emergence will not be changed since this will be determined by the risk of accidental re-introduction. Whether the expense of switching completely from OPV to IPV globally can be justified will depend upon the relative risks of wild poliovirus re-emergence from either OPV-derived sources or other environmental sources including escape of virulent seed viruses from IPV production facilities. This balance of probabilities and risks will be very difficult to determine. In any case, it is likely that the decision to upscale IPV production to required levels has already been delayed too long so that polio eradication will be achieved by the use of OPV in developed as well as in less developed countries that cannot afford to use IPV at a high enough vaccine coverage rate to make it safe. Wild poLiovirus transmission has been interrupted with OPV in the Western Hemisphere. There is no reason why this cannot be done in the rest of the world. In industrialized countries that can afford it and where vaccine coverage is sufficient to prevent wild virus circulation, IPV, in combined vaccines, will be increasingly used. Let us hope that politicians in developing countries and zealous ethicists in the developed world will understand why, in the present and foreseeable future circumstances, OPV is better than IPV in the poorer countries and will not demand, in the name of equity in health, a total switch to IPV. For eradication, IPV cannot, and hopefully need not, replace OPV. At this stage it should not." @default.
• W7870110 created "2016-06-24" @default.
• W7870110 creator A5020399795 @default.
• W7870110 date "2001-01-01" @default.
• W7870110 modified "2023-10-16" @default.
• W7870110 title "Strengths and weaknesses of current polio vaccines--a view from industry." @default.
• W7870110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11763338" @default.
• W7870110 hasPublicationYear "2001" @default.
• W7870110 type Work @default.
• W7870110 sameAs 7870110 @default.
• W7870110 citedByCount "4" @default.
• W7870110 crossrefType "journal-article" @default.
• W7870110 hasAuthorship W7870110A5020399795 @default.
• W7870110 hasConcept C141071460 @default.
• W7870110 hasConcept C159047783 @default.
• W7870110 hasConcept C22070199 @default.
• W7870110 hasConcept C2522874641 @default.
• W7870110 hasConcept C2778715236 @default.
• W7870110 hasConcept C2779631682 @default.
• W7870110 hasConcept C2909513299 @default.
• W7870110 hasConcept C41008148 @default.
• W7870110 hasConcept C4870876 @default.
• W7870110 hasConcept C71924100 @default.
• W7870110 hasConcept C761482 @default.
• W7870110 hasConcept C76155785 @default.
• W7870110 hasConcept C99454951 @default.
• W7870110 hasConceptScore W7870110C141071460 @default.
• W7870110 hasConceptScore W7870110C159047783 @default.
• W7870110 hasConceptScore W7870110C22070199 @default.
• W7870110 hasConceptScore W7870110C2522874641 @default.
• W7870110 hasConceptScore W7870110C2778715236 @default.
• W7870110 hasConceptScore W7870110C2779631682 @default.
• W7870110 hasConceptScore W7870110C2909513299 @default.
• W7870110 hasConceptScore W7870110C41008148 @default.
• W7870110 hasConceptScore W7870110C4870876 @default.
• W7870110 hasConceptScore W7870110C71924100 @default.
• W7870110 hasConceptScore W7870110C761482 @default.
• W7870110 hasConceptScore W7870110C76155785 @default.
• W7870110 hasConceptScore W7870110C99454951 @default.
• W7870110 hasLocation W78701101 @default.
• W7870110 hasOpenAccess W7870110 @default.
• W7870110 hasPrimaryLocation W78701101 @default.
• W7870110 hasRelatedWork W1874486123 @default.
• W7870110 hasRelatedWork W1974306966 @default.
• W7870110 hasRelatedWork W2059685481 @default.
• W7870110 hasRelatedWork W2088363170 @default.
• W7870110 hasRelatedWork W2467936019 @default.
• W7870110 hasRelatedWork W2579288712 @default.
• W7870110 hasRelatedWork W2583889390 @default.
• W7870110 hasRelatedWork W3014988697 @default.
• W7870110 hasRelatedWork W3127797838 @default.
• W7870110 hasRelatedWork W63007482 @default.
• W7870110 hasVolume "105" @default.
• W7870110 isParatext "false" @default.
• W7870110 isRetracted "false" @default.
• W7870110 magId "7870110" @default.
• W7870110 workType "article" @default.